Table 6.

Distribution of CD66b + TANs in esophageal adenocarcinoma

	Amount CD66b + TAN in overall collective (n = 660)		Amount CD66b + TAN in primary surgery cohort (n = 275)		Amount CD66b + TAN in neoadjuvant cohort (n = 385)
	Low	High	Low	High	Low	High
Sex
Male	281 (48.6%)	297 (51.4%)	121 (49.6%)	123 (50.4%)	160 (47.9%)	174 (52.1%)
Female	43 (52.4%)	39 (47.6%)	18 (58.1%)	13 (41.9%)	25 (49.0%)	26 (51.0%)
Age
< 65	155 (46.3%)	180 (53.7%)	54 (47.0%)	61 (53.0%)	101 (45.9%)	119 (54.1%)
> 65	150 (50.8%)	145 (49.2%)	71 (50.0%)	71 (50.0%)	79 (51.6%)	74 (48.4%)
UICC stage
(y)1	54 (38.8%)	85 (61.2%)	30 (38.0%)	49 (62.0%)	24 (40.0%)	36 (60.0%)
(y)2	77 (48.1%)	83 (51.9%)	29 (47.5%)	32 (52.5%)	48 (48.5%)	51 (51.5%)
(y)3	140 (50.7%)	136 (49.3%)	56 (58.9%)	39 (41.1%)	84 (46.4%)	97 (53.6%)
(y)4	48 (61.5%)	30 (38.5%)	21 (60.0%)	14 (40.0%)	27 (62.8%)	16 (37.2%)

UICC Union internationale contre le cancer